Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective

Bishow B Adhikari; Scarlet Shi; Eileen P Dimond; Nonniekaye Shelburne; Patrice Desvigne-Nickens; Lori M Minasian

doi:10.1016/j.hfc.2022.01.001

Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective

Heart Fail Clin. 2022 Jul;18(3):515-528. doi: 10.1016/j.hfc.2022.01.001.

Authors

Bishow B Adhikari¹, Scarlet Shi², Eileen P Dimond³, Nonniekaye Shelburne⁴, Patrice Desvigne-Nickens⁵, Lori M Minasian⁶

Affiliations

¹ Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH6705 Rockledge Drive, Room 313-J, MSC 7956, Bethesda, MD 20892-7956, USA. Electronic address: adhikarb@mail.nih.gov.
² Division of Cardiovascular Sciences, NHLBI, NIH, 6705 Rockledge Drive, Room 313-H, MSC 7956, Bethesda, MD 20817, USA.
³ Division of Cancer Prevention, NCI, NIH, 9609 Medical Center Drive Room 5E332, Bethesda, MD 20892, USA.
⁴ Division of Cancer Control and Population Sciences, NCI, NIH, 9609 Medical Center Drive Room 4E110, Bethesda, MD 20892, USA.
⁵ Division of Cardiovascular Sciences, NHLBI, NIH, 6705 One Rockledge Drive, Room 312-B2, Bethesda, MD 20892-7940, USA.
⁶ Division of Cancer Prevention, NCI, NIH, 9609 Medical Center Dr. Room 5E342, Bethesda, MD 20892, USA.

Abstract

Advances in cancer treatments have led to nearly 17 million survivors in the US today. Cardiovascular complications attributed to cancer treatments are the leading cause of morbidity and mortality in cancer survivors. In response, NCI and NHLBI held 2 workshops and issued funding opportunities to strengthen research on cardiotoxicity. A representative portfolio of NIH grants categorizing basic, interventional, and observational projects is presented. Compared with anthracyclines, research on radiation therapy and newer treatments is underrepresented. Multidisciplinary collaborative research that considers the cardiotoxicity stage and optimizes the balance between cardiovascular risk and cancer-treatment benefit might support continued improvements in cancer outcomes.

Keywords: Cancer therapy; Cancer treatment; Cardiac toxicity; Cardiotoxicity; Cardiovascular complications; Cardiovascular toxicity; Chemotherapy; Radiation injury.

Publication types

Review

MeSH terms

Anthracyclines / therapeutic use
Cardiotoxicity* / etiology
Humans
Medical Oncology
National Institutes of Health (U.S.)
Neoplasms* / drug therapy
Neoplasms* / therapy
United States / epidemiology

Substances

Anthracyclines

Grants and funding

Z99 HL999999/ImNIH/Intramural NIH HHS/United States